NEW ORLEANS — The American Association of Pharmaceutical Scientists (AAPS), a global professional society representing over 7,000 scientists and researchers, has officially announced the appointment of Dr. Patrick J. Sinko, Ph.D., R.Ph., as its new Chief Science Officer (CSO).
The appointment marks a significant strategic shift for the organization, which seeks to bolster its influence in the rapidly evolving landscape of drug discovery, development, and regulatory science. Dr. Sinko, a distinguished professor at Rutgers University, will spearhead the association’s scientific vision, oversee its expansive portfolio of peer-reviewed journals, and curate high-level scientific programming across both digital and in-person platforms, including the flagship PharmSci 360 meeting.
The Strategic Mandate: Leading the Scientific Frontier
As the pharmaceutical industry grapples with the complexities of gene therapies, personalized medicine, and AI-driven drug discovery, the role of the Chief Science Officer has never been more critical. Dr. Sinko’s mandate is clear: to ensure that AAPS remains the premier intellectual hub for the global pharmaceutical community.
In his new role, Dr. Sinko will be responsible for:
- Defining the Scientific Strategy: Aligning the association’s resources with the most pressing global health challenges.
- Curating Content: Overseeing the direction of AAPS journals to maintain rigorous standards of excellence in dissemination.
- Programming Excellence: Directing the educational and technical content for AAPS’s global conferences, ensuring they address the intersection of basic science and clinical application.
"AAPS has long been the intellectual home for pharmaceutical scientists across academia, industry, and regulatory agencies," Dr. Sinko stated upon the announcement. "I am honored to step into the Chief Science Officer role to help shape our scientific vision, foster interdisciplinary collaboration, and deliver cutting-edge programming and publications that address the most urgent challenges in drug discovery and development."
A Career Defined by Innovation: A Chronology
Dr. Sinko’s appointment is the culmination of nearly four decades of service to the field of pharmaceutical sciences. His journey is characterized by a rare duality: the ability to thrive in the rigorous, data-driven environment of academic research while maintaining a pragmatic, entrepreneurial focus on the commercialization of drug delivery systems.
1986: Early Foundations
The year 1986 was a watershed moment for both the AAPS and Dr. Sinko. It was the year the association was founded, and the year Sinko began his long-standing membership. Since the inception of the organization, he has been a consistent voice, rising through the ranks to eventually serve as president.
1991–2007: The Rutgers Era Begins
Dr. Sinko joined the faculty of the Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey, in 1991. Over the following three decades, he established a world-class laboratory focused on biopharmaceutics and drug delivery. His contributions to the university reached an administrative pinnacle between 2007 and 2018, when he served as the Associate Vice President for Research, helping to guide the university’s massive research enterprise.
1998: The Entrepreneurial Pivot
Proving that he was not merely an ivory-tower academic, Sinko co-founded NaviCyte, a pioneering absorption-screening company. His work in the private sector continued with the formation of Theraport Biosciences, where he served as Chief Science Officer. These ventures were instrumental in bridging the gap between bench-top research and therapeutic reality, with NaviCyte eventually being acquired by Trega Biosciences.
2000s–Present: Editorial Leadership and Global Influence
Beyond the lab, Dr. Sinko became a voice for the profession. Taking over as editor of Martin’s Physical Pharmacy and Pharmaceutical Sciences starting with the fifth edition, he has helped shape the education of thousands of pharmacy students. His current role as Editor-in-Chief of Pharmaceutics (MDPI) reinforces his commitment to the rapid dissemination of peer-reviewed research.
Supporting Data: A Legacy of Excellence
The appointment of Dr. Sinko is backed by a body of work that is, by any metric, prolific. His credentials provide a robust foundation for the leadership role he now assumes at AAPS.
Academic and Professional Impact
- Publication Record: Dr. Sinko has authored or co-authored more than 475 publications, including seminal research papers, critical reviews, and textbook chapters.
- Mentorship: A testament to his commitment to the next generation, he has personally trained and mentored approximately 110 students and postdoctoral fellows, many of whom are now leaders in the pharmaceutical industry.
- Continuous Funding: For over 30 years, Sinko has maintained continuous funding from the National Institutes of Health (NIH) and various industry partners—a feat that highlights the sustained relevance of his research into pharmaceutical formulations and delivery systems.
Honors and Fellowships
Dr. Sinko’s work has been recognized by the most prestigious institutions in science:
- NIH Recognition: Recipient of the prestigious NIH FIRST and MERIT awards.
- Institutional Excellence: Honored with the Rutgers Board of Trustees Award for Excellence in Research.
- Fellowships: He is an elected fellow of the American Association for the Advancement of Science (AAAS), AAPS, the Controlled Release Society, and the National Academy of Inventors.
Implications for the Pharmaceutical Industry
The selection of a CSO with such a diverse background—spanning academic research, commercial entrepreneurship, and professional association leadership—signals a proactive stance by AAPS.
Bridging the Gap
The pharmaceutical industry currently faces a "translation gap," where groundbreaking basic science often struggles to make the leap to human clinical trials. By placing a leader who understands both the rigor of academic peer-review and the pressures of private-sector drug development, AAPS is positioning itself to be a catalyst for better translational outcomes.
Elevating Regulatory Science
With his background in biopharmaceutics and drug delivery, Dr. Sinko is uniquely suited to guide discussions around regulatory pathways. As new modalities such as mRNA, monoclonal antibodies, and nanotechnology-based delivery systems become the standard, the scientific community looks to AAPS for guidance on safety and efficacy standards. Sinko’s leadership will likely facilitate stronger dialogue between the FDA, EMA, and the scientists who develop these technologies.
The 2026 PharmSci 360 Outlook
The upcoming PharmSci 360 meeting in New Orleans (October 25–28, 2026) will serve as the first major platform for Dr. Sinko to showcase his vision. The conference is expected to draw thousands of global experts to the Ernest N. Morial Convention Center. Industry analysts suggest that under Sinko’s guidance, attendees can expect a stronger emphasis on interdisciplinary programming—merging the fields of materials science, data analytics, and molecular biology.
Conclusion: A New Chapter for AAPS
The appointment of Dr. Patrick J. Sinko is more than a personnel move; it is a declaration of intent. By leveraging his deep-seated academic roots and his proven track record in the private sector, AAPS is preparing to navigate a future defined by rapid technological disruption.
As the association looks toward its next decade of influence, the leadership of Dr. Sinko promises to bridge the traditional silos of academia and industry, ensuring that the pharmaceutical sciences continue to be a primary driver of global public health improvement. For the 7,000+ members of AAPS, the message is clear: the association is committed to providing the intellectual, technical, and strategic resources necessary to turn the complex challenges of today into the medical breakthroughs of tomorrow.
About AAPS
The American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific organization of approximately 7,000 members employed in academia, industry, government, and other research institutes worldwide. Founded in 1986, AAPS provides a dynamic, international forum for the exchange of knowledge among scientists to enhance their contributions to health. For more information, visit www.aaps.org.
About the Author
